Study backs increased PSA screening for younger African Americans
Study results presented during the 2021 ASCO Annual Meeting showed an association between increased prostate-specific antigen (PSA) screening and improved outcomes in younger African American patients.
In this video, lead study author Edmund M. Qiao, a medical student at the University of California San Diego, discusses how the results show that in younger African Americans, an increase in the frequency of PSA screening was linked to a nearly 25% reduction in prostate cancer–specific mortality and an approximately 40% lower risk of having metastatic disease at the time of a prostate cancer diagnosis. Based on their findings, the researchers recommend that younger African Americans begin having discussions early with their physicians regarding whether they need screening.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
